US FDA Approves Expanded Zytiga® Indication for Treatment of Metastatic Castration-Resistant Prostate Cancer
On Monday 10 December pharmaceutical company Janssen announced that the US Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA® (abiraterone acetate). This means the drug will be available to men who have not previously had chemotherapy.
Men with metastatic disease now have some good news about new treatment options as they battle with advanced disease.
Note: this applies to the US only.